Diabetic eye disease: The urgent need for early, non-invasive treatments
Dr Catherine Beech, CEO at Exonate and Dr Pete Adamson, CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Diabetic retinal disease, termed diabetic retinopathy (DR), is a significant risk factor for people with Type I or II… Read More
